RT Journal Article
SR Electronic
T1 SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 415
OP 423
DO 10.3949/ccjm.91a.23093
VO 91
IS 7
A1 Jaswaney, Rahul
A1 Sokoloff, Samantha
A1 Rakita, Val
A1 Rubin, Daniel J.
YR 2024
UL http://www.ccjm.org/content/91/7/415.abstract
AB Despite current therapies, heart failure and chronic kidney disease continue to be major causes of morbidity and mortality. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have recently become standard-of-care therapy for these conditions. This review summarizes important randomized controlled trials of SGLT-2 inhibitors and guidelines for using these agents in patients with heart failure and chronic kidney disease in both clinic and hospital settings.